Dashboard
Company has a low Debt to Equity ratio (avg) at times
Poor long term growth as Net Sales has grown by an annual rate of 4.86% over the last 5 years
With ROE of 6.38%, it has a fair valuation with a 1.65 Price to Book Value
High Institutional Holdings at 88.11%
Market Beating performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
USD 302 Million (Micro Cap)
26.00
NA
0.00%
-0.49
9.08%
1.92
Total Returns (Price + Dividend) 
Nature's Sunshine Products, Inc. for the last several years.
Risk Adjusted Returns v/s 
News

Nature's Sunshine Products, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Metrics
Nature's Sunshine Products, Inc. has recently adjusted its valuation, with its stock price at $14.10. Over the past year, the company has achieved a stock return of 10.76%. Key financial metrics include a P/E ratio of 26 and a return on capital employed of 27.36%, reflecting its position in the Pharmaceuticals & Biotechnology sector.
Read MoreIs Nature's Sunshine Products, Inc. overvalued or undervalued?
As of 17 October 2025, the valuation grade for Nature's Sunshine Products, Inc. has moved from attractive to fair. The company is currently overvalued based on its valuation metrics. The P/E ratio stands at 26, which is significantly higher than the peer average of 21.11 for companies like Chromadex Corp. and USANA Health Sciences, Inc., which have P/E ratios of 39.82 and 16.23, respectively. Additionally, the EV to EBITDA ratio of 5.08 is also elevated compared to the peer average of 6.47. Nature's Sunshine Products, Inc. has shown a return of 6.30% over the past year, which is notably lower than the S&P 500's return of 14.08% during the same period, reinforcing the notion that the stock is overvalued in the current market context....
Read More
Nature's Sunshine Products, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics
Nature's Sunshine Products, Inc. has recently adjusted its valuation, with its stock price at $14.18. Over the past year, it has returned 6.30%, underperforming the S&P 500. Key metrics include a P/E ratio of 26 and a ROCE of 27.36%, indicating its competitive positioning in the Pharmaceuticals & Biotechnology sector.
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Domestic Funds
Held in 43 Schemes (19.56%)
Held by 30 Foreign Institutions (18.93%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is 1.33% vs -4.23% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is 12.24% vs 800.00% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 2.04% vs 5.55% in Dec 2023
YoY Growth in year ended Dec 2024 is -51.83% vs 2,633.33% in Dec 2023






